Clinical Trial

Radiomics and Molecular Classification in Endometrial Cancer

Study acronym: ROME
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Molecular/genomic profiling is the most accurate method to assess the prognosis of endometrial cancer patients. Interestingly, the adoption of radiomics showed important results, across various oncologic specialties. Radiomic allows extracting mineable high-dimensional data from clinical images, thus providing a number of noteworthy information of the tumor tissues. We aim to correlate radiomic features obtained from ultrasound images with the molecular/genomic profiling to identify new hallmarks for stratification of endometrial cancer patients into different classes of risk The central hypothesis is that combining radiomic features might allow identifying various classes of risk for endometrial cancer. The rationale for the proposed research is that once validated, radiomics applied to ultrasonographic images would be an effective, innovative, and cheap method for tailor operative and postoperative treatment modality in endometrial cancer.
Trial Details
NCT Number NCT06963385
Lead Sponsor Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Conditions Endometrial Cancer, Uterine Cancer, Endometrium Tumor
Enrollment 250 participants
Start Date 2021-01-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-09